2Seventy Bio

2Seventy Bio is one of the...

• Russell 3000.

2Seventy Bio is a company listed under the stock ticker TSVT (US).

View the org chart displaying its 21 main executives

Most searched biographies at 2Seventy Bio

• Sarah Glickman, Director
• Dan Lynch, Director
• Marcela Maus, Director

Popular executive movements at 2Seventy Bio

• Charles Newton has joined the company as Director  (posted on March 21 2024).
• Eli Casdin has joined the company as Director  (posted on March 21 2024).
• William Baird who was Chief Financial Officer, becomes Chief Operating Officer  (posted on September 13 2023).

Create your alert
to follow the executive moves at 2Seventy Bio.

2Seventy Bio has 2,273 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).
• Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).
• Nuvation Bio has announced the acquisition of AnHeart  (posted on April 12 2024).

Popular contacts in Biotechnology

• Vik Bajaj - Director at Interline Therapeutics
• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by 2Seventy Bio

• 2seventy bio to Participate in Upcoming Investor Conferences | 2seventy Bio
• News Releases | 2seventy Bio
• 2seventy bio to Participate in Upcoming Investor Conferences | 2seventy Bio
• 2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference | 2seventy Bio
• 2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference | 2seventy Bio
• 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress | 2seventy Bio
• 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress | 2seventy Bio
• 2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting | 2seventy Bio
• 2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting | 2seventy Bio
• 2seventy bio to Participate in CG Horizons in Oncology Virtual Conference | 2seventy Bio
• View more press releases Close

Social media about 2Seventy Bio

• 2Seventy Bio on Wikipedia, Google News & Yahoo Finance
• 2Seventy Bio on LinkedIn, Twitter & YouTube

Contact by email its executives including Eli Casdin

Call 2Seventy Bio at +1 339...

View the org chart

Register to receive your alert

Report an error